Oklahoma Medical Research Foundation
Founded in 1946, this independent nonprofit biomedical research institute conducts basic, translational, and clinical research in critical areas such as heart disease, cancer, autoimmune, and neurodegenerative diseases. Its mission focuses on understanding biological mechanisms and advancing diagnostics and therapeutics. Activities include conducting clinical trials, managing a patent portfolio, commercializing biotechnologies, and supporting the biotech community. Research efforts are funded by grants and philanthropy, and the institute hosts advanced facilities, interdisciplinary research teams, and collaborations with academia and industry.
Industries
N/A
Patents
Biomarkers for a systemic lupus erythematosus (SLE) disease activity immune index that characterizes disease activity
2025-12-30 • US-12510539-B2
View DetailsPeripheral blood DNA methylation models as predictors of knee osteoarthritis radiographic progression
2025-11-11 • US-12467092-B2
View DetailsBiomarkers for assessing risk of transitioning to systemic lupus erythematosus classification and disease pathogenesis
2024-11-12 • US-12140592-B2
View Details
Biomarkers for a systemic lupus erythematosus (SLE) disease activity immune index that characterizes disease activity
2025-12-30 • US-12510539-B2
View DetailsPeripheral blood DNA methylation models as predictors of knee osteoarthritis radiographic progression
2025-11-11 • US-12467092-B2
View DetailsBiomarkers for assessing risk of transitioning to systemic lupus erythematosus classification and disease pathogenesis
2024-11-12 • US-12140592-B2
View DetailsServices
Offers clinical evaluations for adults and families affected by autoimmune conditions, including laboratory and specialist assessment.
Provides neurological consultation, disease management, therapy, cognitive assessment, infusion, spasticity management, mobility evaluation, and coordination of care for multiple sclerosis patients.
Performs comprehensive sequencing and genotyping projects for researchers and collaborators, including NGS and single-cell analyses.
Offers clinical evaluations for adults and families affected by autoimmune conditions, including laboratory and specialist assessment.
Provides neurological consultation, disease management, therapy, cognitive assessment, infusion, spasticity management, mobility evaluation, and coordination of care for multiple sclerosis patients.
Performs comprehensive sequencing and genotyping projects for researchers and collaborators, including NGS and single-cell analyses.
Expertise Areas
- Immunology and cancer research
- Cardiovascular biology
- Neurodegenerative disease research
- Autoimmune disease research
Key Technologies
- Molecular diagnostics
- Antibody development
- Animal models
- Clinical assay development
Key People
Vice President, Technology Ventures
Research Integrity Officer
Associate Research Scientist, Immunobiology & Cancer Research Program
Associate Research Scientist, Protein Studies Research Program
Associate Research Scientist, Immunobiology & Cancer Research Program
Associate Research Scientist, Protein Studies Research Program
Vice President, Technology Ventures
Research Integrity Officer
Associate Research Scientist, Immunobiology & Cancer Research Program
Associate Research Scientist, Protein Studies Research Program
Associate Research Scientist, Immunobiology & Cancer Research Program
Associate Research Scientist, Protein Studies Research Program
News & Updates
Contributed to the development and advancement of three therapeutics that reached the market.
Achieved significant patent portfolio in biomedical research.
Achieved high ranking among independent research institutes for grant acquisition.
An investigational drug for glioblastoma developed at OMRF advances to further clinical trials with Korean pharmaceutical partners.
Exclusive licensing agreement for a novel chemotherapeutic drug to treat liver cancer.
Grant awarded for work combining multiple sclerosis treatment, disease management, and research.
Contributed to the development and advancement of three therapeutics that reached the market.
Achieved significant patent portfolio in biomedical research.
Achieved high ranking among independent research institutes for grant acquisition.
An investigational drug for glioblastoma developed at OMRF advances to further clinical trials with Korean pharmaceutical partners.
Exclusive licensing agreement for a novel chemotherapeutic drug to treat liver cancer.
Grant awarded for work combining multiple sclerosis treatment, disease management, and research.